Thanks for sharing your opinion regarding trial design concerns but I'd point out that the MHRA believes those concerns are bullshit as they approved a pediatric trial using the same trial design.
Sorry, your argument carries no weight. Any restart of treatment schedule is not double dosing it was part of the agreed to treatment plan by FDA and if treatment is “just a placebo” ie no better than grapefruit juice then there will be no benefit. There is also a reason why only 5 doses were required to be made from tumor lysate for entry into this trial and that is because immune memory is created by this point generally or not. This is validated by the combo trial that requires only 3 doses to be made for entry and the early data suggests that with those 3 doses about 60% of patients will survive 10 years. The merry-go-round is broken. Time to move on. Best wishes.
Market Data 
Markets 
AI
